Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1100 participants.
Also called NCT02722447
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,100 participants
- Sponsor
- Walter Ageno
- Registry
-
NCT02722447
-
- Other papers using this trial's data
- Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT02722447. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2019-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
- Acronym
- RIDTS
- Condition
- Deep Vein Thrombosis
- Intervention (Drug)
- rivaroxaban
- Intervention (Drug)
- Placebo
- Lead sponsor
- Walter Ageno
Record details
- Record id
cardio:ct-nct02722447- Content hash
6cc0f42c95be21a27377b9ee51a5e2ee1bfec1870e804d3ebe483217d31bd9a2